Researchers at Duke University say in a 3-year study, a single, intravenous infusion of the drug Oritavancin was just as effective in treating resistant infections as the current standard drug, Vancomycin, which is taken twice a day for up to ten days.
Researchers say a key advantage to the new drug is that it can stay in the body for a longer period of time. The study author says, "you can be discharged from the ER to go back home and gradually cure the infection over the next 7 to 10 days.
The drug maker funded the study and has submitted the results to the FDA. Researchers say there were minor side effects, including nausea and headaches.
Copyright 2016 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.